This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Rice ASC et al. (2007) Cannabinoids and analgesia with special reference to neuropathic pain. In Systematic Reviews and Meta-Analyses in Pain, 233–246 (Eds McQuay HJ. et al.) Seattle: IASP Press
Svendsen KB et al. (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329: 253–257
Rog DJ et al. (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65: 812–819
Rice ASC (2008) Cannabinoids for neuropathic pain? Where next? Neuropathic Pain 11: 3–6 [http://www.neupsig.org]
Frank B et al. (2008) Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 336: 199–201
Nurmikko TJ et al. (2007) Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133: 210–220
Abrams DI et al. (2007) Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68: 515–521
Ellis RJ et al. (2008) Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology [10.1038/npp.2008.120]
Wang T et al. (2008) Adverse effects of medical cannabinoids: a systematic review. CMAJ 178: 1669–1678
Semple DM et al. (2005) Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 19: 187–194
Moore TH et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319–328
Zammit S et al. (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325: 1199–2005
Henquet C et al. (2005) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330: 11
Caspi A et al. (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57: 1117–1127
Author information
Authors and Affiliations
Ethics declarations
Competing interests
ASC Rice is a patent holder/applicant with Imperial Innovations, has received a grant or research support from Pfizer and Spiniflex, and is a consultant for Pfizer, BTG, GlaxoSmithKline, Eisai, Allergan, Solvay, Organon (Schering–Plough) and Lectus Therapeutics. He is also named as inventor on a palmitoylethanolamide-related patent (WO 2005/079771).
Rights and permissions
About this article
Cite this article
Rice, A. Should cannabinoids be used as analgesics for neuropathic pain?. Nat Rev Neurol 4, 654–655 (2008). https://doi.org/10.1038/ncpneuro0949
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0949